MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
NEW YORK, March 13, 2018 -- In a release issued under the same headline earlier today by Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) please note that the conference date should be March 20, not March 19 as previously stated. The corrected release follows.
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 20, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
